{"product_id":"platinum-based-chemotherapy-before-surgery-for-triple-negative-breast-cancer-what-patients-need-to-know","title":"Platinum-Based Chemotherapy Before Surgery for Triple-Negative Breast Cancer: What Patients Need to Know","description":"\u003cp\u003eTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that accounts for 10-20% of all breast tumors. This comprehensive meta-analysis of nine randomized controlled trials involving 2,109 patients examined whether adding platinum-based chemotherapy drugs (carboplatin or cisplatin) to standard neoadjuvant chemotherapy (treatment given before surgery) improves outcomes for TNBC patients. The researchers found that platinum-based regimens significantly increased the rate of pathological complete response (pCR) from 37.0% to 52.1% (OR 1.96, 95% CI 1.46–2.62, P\u0026lt;0.001), meaning more patients had no residual invasive cancer at the time of surgery. However, this benefit came at the cost of significantly higher rates of serious hematological side effects, including neutropenia, anemia, and thrombocytopenia. Notably, the benefit was not observed in patients with BRCA gene mutations, and no significant improvement in event-free survival or overall survival was demonstrated.\u003c\/p\u003e\n\n\u003ch1\u003ePlatinum-Based Chemotherapy Before Surgery for Triple-Negative Breast Cancer: What Patients Need to Know\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding Triple-Negative Breast Cancer and Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pcr\"\u003eKey Finding: Pathological Complete Response Rates\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#brca\"\u003eWhat About Patients with BRCA Gene Mutations?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#survival\"\u003eSurvival Outcomes: Event-Free and Overall Survival\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSide Effects: The Cost of Adding Platinum Agents\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAdding platinum to neoadjuvant chemotherapy raised complete response rates from 37.0% to 52.1% in 2,109 TNBC patients.\u003c\/li\u003e\n\u003cli\u003eBenefit was consistent across chemotherapy backbones, including weekly paclitaxel followed by anthracycline plus cyclophosphamide.\u003c\/li\u003e\n\u003cli\u003eIn 96 BRCA-mutated patients, platinum did not significantly increase complete response rates, but numbers were small.\u003c\/li\u003e\n\u003cli\u003ePlatinum increased severe neutropenia (3x), anemia (15x), and thrombocytopenia (8x), but not neuropathy.\u003c\/li\u003e\n\u003cli\u003eSurvival data from two trials showed no significant improvement in event-free or overall survival with platinum.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding Triple-Negative Breast Cancer and Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eTriple-negative breast cancer (TNBC) is a particularly challenging form of breast cancer that accounts for approximately 10%–20% of all breast tumors. Unlike other breast cancer subtypes, TNBC cells do not have receptors for estrogen, progesterone, or the HER2 protein—hence the name \"triple-negative.\" This means that hormone therapies and HER2-targeted treatments that work well for other breast cancer types are not effective for TNBC patients.\u003c\/p\u003e\n\n\u003cp\u003eDespite its aggressive behavior, TNBC has a unique characteristic that researchers call the \"triple negative paradox\": it is particularly sensitive to cytotoxic (cell-killing) chemotherapy. In the neoadjuvant setting—meaning chemotherapy given before surgery to shrink tumors—TNBC patients show higher response rates compared to women with hormone receptor-positive breast cancer. Approximately 30%–40% of TNBC patients achieve a pathological complete response (pCR) after standard chemotherapy that includes anthracyclines, cyclophosphamide, and taxanes.\u003c\/p\u003e\n\n\u003cp\u003eAchieving pCR—defined as no residual invasive tumor in both the breast and the axilla (underarm lymph nodes)—has strong prognostic value in TNBC patients, even stronger than in other breast cancer subtypes. This is why neoadjuvant chemotherapy is currently considered the preferred approach for the majority of TNBC patients with early-stage disease.\u003c\/p\u003e\n\n\u003cp\u003ePlatinum agents, specifically carboplatin and cisplatin, are cytotoxic DNA-damaging compounds that work by causing DNA strand breaks, which can lead to cell death. This mechanism makes them especially active in cancer cells with DNA repair deficiencies, such as those harboring deleterious mutations in the BRCA genes. Based on the biological rationale that TNBC cells may be particularly susceptible to DNA-damaging compounds, several trials have investigated platinum agents as a treatment option for TNBC patients.\u003c\/p\u003e\n\n\u003cp\u003eHowever, the results from these studies have been mixed and controversial. According to current breast cancer guidelines at the time of this research, the addition of a platinum agent to standard neoadjuvant chemotherapy in unselected TNBC patients was not recommended, though its use could be considered in breast cancer patients with deleterious germline BRCA mutations. This meta-analysis was conducted to provide up-to-date evidence on this important and controversial topic.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis study was a systematic review and meta-analysis, which is a rigorous method of combining and analyzing results from multiple independent studies to draw stronger conclusions than any single study could provide. The researchers conducted a systematic search of the Medline and Web of Science databases, with no language or date restrictions, up to October 30, 2017.\u003c\/p\u003e\n\n\u003cp\u003eThe search strategy used the following keywords: \"breast cancer,\" \"platinum,\" \"carboplatin,\" \"cisplatin,\" \"neoadjuvant,\" and \"chemotherapy.\" The researchers also reviewed conference proceedings from major oncology meetings, including the European Society for Medical Oncology (ESMO) congress, the American Society of Clinical Oncology (ASCO) annual meeting, and the San Antonio Breast Cancer Symposium (SABCS), to identify relevant unpublished studies.\u003c\/p\u003e\n\n\u003cp\u003eTo be included in this meta-analysis, studies had to meet specific criteria: they had to be phase II or III randomized controlled trials (RCTs); they had to include TNBC patients who received platinum-based neoadjuvant chemotherapy in the experimental arm and platinum-free neoadjuvant chemotherapy in the control arm; and they had to have available information on pCR rates in both arms. For RCTs that included patients with breast cancer subtypes other than TNBC, only those with available results in the TNBC cohort were included.\u003c\/p\u003e\n\n\u003cp\u003eThe initial literature search returned 1,328 records. After excluding 1,316 non-relevant records, 12 potentially eligible RCTs were considered. Among these, two were updates of previously published studies and one was a secondary analysis of an already included RCT. This left nine different RCTs for inclusion in the final meta-analysis.\u003c\/p\u003e\n\n\u003cp\u003eTwo of the nine RCTs were published only in abstract form. Two RCTs conducted by the German Breast Group included both TNBC and HER2-positive breast cancer patients, and one RCT (UMIN000003355) also included hormone receptor-positive\/HER2-negative breast cancer patients—for the purpose of this meta-analysis, only data pertaining to TNBC patients from these trials were considered.\u003c\/p\u003e\n\n\u003cp\u003eA total of 2,109 TNBC patients were included in the analysis, with 1,046 (49.6%) receiving platinum-based chemotherapy and 1,063 (50.4%) receiving platinum-free chemotherapy. All but one of the RCTs used carboplatin as the platinum agent; one study used cisplatin.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers calculated pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CI) for pathological complete response, event-free survival (EFS), overall survival (OS), and grade 3 and 4 adverse events including neutropenia, anemia, thrombocytopenia, and neuropathy. An OR greater than 1 indicates higher pCR rates in the platinum-based group, while an HR less than 1 indicates improved survival outcomes with platinum-based chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eThe study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered with the PROSPERO registration number CRD42018080042.\u003c\/p\u003e\n\n\u003ch2 id=\"pcr\"\u003eKey Finding: Pathological Complete Response Rates\u003c\/h2\u003e\n\n\u003cp\u003eThe primary objective of this meta-analysis was to compare the activity of platinum-based versus platinum-free neoadjuvant chemotherapy in TNBC patients, measured by pCR rates. The results were striking.\u003c\/p\u003e\n\n\u003cp\u003eOverall, including all nine RCTs, 938 of 2,109 patients (44.5%) achieved a pCR after neoadjuvant treatment. Breaking this down by treatment group:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e545 of 1,046 patients (52.1%) in the platinum-based chemotherapy group achieved pCR\u003c\/li\u003e\n  \u003cli\u003e393 of 1,063 patients (37.0%) in the platinum-free chemotherapy group achieved pCR\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis difference was highly statistically significant (OR 1.96, 95% CI 1.46–2.62, P\u0026lt;0.001), meaning that patients receiving platinum-based chemotherapy were approximately twice as likely to achieve a complete pathological response. The statistical significance level of P\u0026lt;0.001 indicates there is less than a 0.1% chance that this finding was due to random chance.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers conducted several subgroup analyses to better understand these results. In the seven RCTs (N=1,698 patients) that used anthracycline- and taxane-based chemotherapy in both treatment arms, the pCR rate was 53.9% (461 of 856) in the platinum-based group versus 39.9% (336 of 842) in the platinum-free group (OR 1.85, 95% CI 1.31–2.61, P\u0026lt;0.001).\u003c\/p\u003e\n\n\u003cp\u003eIn the five RCTs (N=1,234 patients) that used the same chemotherapy backbone in both groups (with or without carboplatin), the pCR rate was 54.2% (338 of 623) in the platinum-based group versus 37.1% (227 of 611) in the platinum-free group (OR 2.04, 95% CI 1.39–3.00, P\u0026lt;0.001).\u003c\/p\u003e\n\n\u003cp\u003eMost importantly, in the three RCTs (N=611 patients) that used the same standard neoadjuvant chemotherapy regimen of weekly paclitaxel (with or without carboplatin) followed by anthracycline plus cyclophosphamide in both groups, the benefit of adding platinum was even more pronounced:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e169 of 308 patients (54.9%) in the platinum-based group achieved pCR\u003c\/li\u003e\n  \u003cli\u003e101 of 303 patients (33.3%) in the platinum-free group achieved pCR\u003c\/li\u003e\n  \u003cli\u003eOR 2.53, 95% CI 1.37–4.66, P=0.003\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSensitivity analyses confirmed that the pooled estimates were stable and did not depend on any single study. The funnel plot and Harbord's asymmetry test (P=0.282) showed no evidence of publication bias, meaning it is unlikely that studies with negative results were systematically missing from the analysis.\u003c\/p\u003e\n\n\u003ch2 id=\"brca\"\u003eWhat About Patients with BRCA Gene Mutations?\u003c\/h2\u003e\n\n\u003cp\u003eOne of the most clinically important questions addressed by this meta-analysis was whether the benefit of platinum-based chemotherapy differs based on germline BRCA mutational status. This is particularly relevant because platinum agents are known to be especially active in cancer cells with DNA repair deficiencies, such as those with BRCA mutations.\u003c\/p\u003e\n\n\u003cp\u003eGermline BRCA mutational status was available for 609 patients in two RCTs. A total of 96 BRCA-mutated patients were included: 50 of 291 patients (17.2%) in the GeparSixto GBG66 study and 46 of 318 patients (14.5%) in the BrighTNess trial.\u003c\/p\u003e\n\n\u003cp\u003eSurprisingly, among BRCA-mutated patients, the addition of carboplatin was \u003cstrong\u003enot\u003c\/strong\u003e associated with a significantly increased pCR rate:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e29 of 50 BRCA-mutated patients (58.0%) in the platinum-based group achieved pCR\u003c\/li\u003e\n  \u003cli\u003e25 of 46 BRCA-mutated patients (54.3%) in the platinum-free group achieved pCR\u003c\/li\u003e\n  \u003cli\u003eOR 1.17, 95% CI 0.51–2.67, P=0.711\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis result was not statistically significant, meaning the researchers could not demonstrate a benefit from adding platinum in BRCA-mutated patients. However, it is important to note that the number of BRCA-mutated patients was small (only 96 total), which limits the statistical power of this analysis.\u003c\/p\u003e\n\n\u003cp\u003eIn contrast, among the 513 patients without BRCA mutations, the benefit of platinum-based chemotherapy was highly significant:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e146 of 256 patients (57.0%) in the platinum-based group achieved pCR\u003c\/li\u003e\n  \u003cli\u003e84 of 257 patients (32.7%) in the platinum-free group achieved pCR\u003c\/li\u003e\n  \u003cli\u003eOR 2.72, 95% CI 1.71–4.32, P\u0026lt;0.001\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis finding is counterintuitive given the biological rationale that platinum agents should be most effective in BRCA-mutated tumors. The researchers noted that this unexpected result may be due to the small sample size of BRCA-mutated patients and the fact that the analysis was not pre-specified. It is also possible that BRCA-mutated TNBC tumors are inherently more chemosensitive, making the additional benefit of platinum less detectable.\u003c\/p\u003e\n\n\u003ch2 id=\"survival\"\u003eSurvival Outcomes: Event-Free and Overall Survival\u003c\/h2\u003e\n\n\u003cp\u003eWhile pCR rates are an important early indicator of treatment effectiveness, the ultimate goal of cancer treatment is to improve survival. Only two RCTs (N=748 patients) reported survival outcomes in this meta-analysis.\u003c\/p\u003e\n\n\u003cp\u003eThe median follow-up was 39 months in the CALGB study and 47.3 months in the GeparSixto GBG66 study. The results for survival outcomes showed no statistically significant differences between the platinum-based and platinum-free groups:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEvent-free survival (EFS):\u003c\/strong\u003e HR 0.72, 95% CI 0.49–1.06, P=0.094\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverall survival (OS):\u003c\/strong\u003e HR 0.86, 95% CI 0.46–1.63, P=0.651\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhile the HR for EFS (0.72) suggests a potential 28% reduction in the risk of events (such as cancer recurrence or death) with platinum-based chemotherapy, this result did not reach statistical significance. The confidence interval (0.49–1.06) includes 1.0, which means the true effect could range from a 51% reduction to a 6% increase in events.\u003c\/p\u003e\n\n\u003cp\u003eThe lack of significant survival benefit is an important finding. It suggests that while platinum-based chemotherapy improves pCR rates, this improvement may not translate into better long-term survival outcomes. However, the researchers noted that only two trials reported survival data, and longer follow-up from more trials is needed to draw definitive conclusions about survival benefits.\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSide Effects: The Cost of Adding Platinum Agents\u003c\/h2\u003e\n\n\u003cp\u003eImproving pCR rates is meaningless if the treatment causes unacceptable toxicity. The researchers therefore carefully analyzed the rates of grade 3 and 4 adverse events (AEs)—the most severe side effects—in both treatment groups. The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 or 4.0 was used to classify adverse events in the included RCTs.\u003c\/p\u003e\n\n\u003cp\u003eThe safety analysis revealed a significantly higher risk of hematological (blood-related) toxicities with platinum-based chemotherapy, but no increased risk of neuropathy (nerve damage). Here are the specific findings:\u003c\/p\u003e\n\n\u003ch3\u003eNeutropenia (Low White Blood Cell Count)\u003c\/h3\u003e\n\u003cp\u003eSeven RCTs reported rates of grade 3 and 4 neutropenia. Overall, 772 of 2,030 patients (37.8%) developed this complication:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e535 of 1,007 patients (53.1%) in the platinum-based group\u003c\/li\u003e\n  \u003cli\u003e237 of 1,023 patients (23.2%) in the platinum-free group\u003c\/li\u003e\n  \u003cli\u003eOR 3.19, 95% CI 1.55–6.54, P=0.002\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis means patients receiving platinum-based chemotherapy were more than three times more likely to experience severe neutropenia, which increases the risk of serious infections.\u003c\/p\u003e\n\n\u003ch3\u003eAnemia (Low Red Blood Cell Count)\u003c\/h3\u003e\n\u003cp\u003eSix RCTs reported rates of grade 3 and 4 anemia. Overall, 108 of 1,939 patients (5.6%) developed this complication:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e104 of 960 patients (10.8%) in the platinum-based group\u003c\/li\u003e\n  \u003cli\u003e4 of 979 patients (0.4%) in the platinum-free group\u003c\/li\u003e\n  \u003cli\u003eOR 15.01, 95% CI 4.86–46.30, P\u0026lt;0.001\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSevere anemia was dramatically more common with platinum-based chemotherapy—patients were 15 times more likely to experience this side effect. Anemia can cause severe fatigue, shortness of breath, and may require blood transfusions.\u003c\/p\u003e\n\n\u003ch3\u003eThrombocytopenia (Low Platelet Count)\u003c\/h3\u003e\n\u003cp\u003eSeven RCTs reported rates of grade 3 and 4 thrombocytopenia. Overall, 121 of 2,030 patients (6.0%) developed this complication:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e111 of 1,007 patients (11.0%) in the platinum-based group\u003c\/li\u003e\n  \u003cli\u003e10 of 1,023 patients (1.0%) in the platinum-free group\u003c\/li\u003e\n  \u003cli\u003eOR 8.32, 95% CI 2.88–23.98, P\u0026lt;0.001\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePatients receiving platinum-based chemotherapy were more than eight times more likely to develop severe thrombocytopenia, which increases the risk of bleeding and bruising.\u003c\/p\u003e\n\n\u003ch3\u003eNeuropathy (Nerve Damage)\u003c\/h3\u003e\n\u003cp\u003eSix RCTs reported rates of grade 3 and 4 neuropathy. Overall, 70 of 1,937 patients (3.6%) developed this complication. Importantly, there was \u003cstrong\u003eno significant difference\u003c\/strong\u003e between the two groups, meaning the addition of platinum agents did not increase the risk of severe nerve damage, which can cause pain, numbness, and tingling in the hands and feet.\u003c\/p\u003e\n\n\u003cp\u003eThese findings highlight an important trade-off: platinum-based chemotherapy significantly improves pCR rates but at the cost of substantially higher rates of serious blood-related side effects. Patients considering this treatment approach need to weigh these benefits and risks carefully with their healthcare team.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis meta-analysis provides the most comprehensive evidence to date on the role of platinum-based neoadjuvant chemotherapy in TNBC patients. The findings have several important implications for clinical practice and patient care.\u003c\/p\u003e\n\n\u003cp\u003eFirst, the addition of platinum agents to standard neoadjuvant chemotherapy significantly increases the likelihood of achieving a pCR in TNBC patients. The absolute increase in pCR rate was approximately 15 percentage points (from 37.0% to 52.1%), which is clinically meaningful. Achieving pCR is strongly associated with better long-term outcomes in TNBC patients, making this an important goal of neoadjuvant treatment.\u003c\/p\u003e\n\n\u003cp\u003eSecond, the benefit of adding platinum appears consistent across different chemotherapy backbones, including the standard regimen of weekly paclitaxel followed by anthracycline plus cyclophosphamide. This suggests that the benefit is not limited to a specific chemotherapy combination.\u003c\/p\u003e\n\n\u003cp\u003eThird, the finding that BRCA-mutated patients did not appear to benefit from platinum addition is surprising and clinically relevant. While this may be due to the small number of BRCA-mutated patients in the analysis, it challenges the assumption that platinum agents are particularly beneficial in this population. Patients with BRCA mutations should discuss this finding with their oncologists, as the decision to add platinum should be individualized.\u003c\/p\u003e\n\n\u003cp\u003eFourth, the lack of significant improvement in event-free and overall survival is a cautionary note. While pCR rates improved, this did not translate into statistically significant survival benefits in the two trials that reported these outcomes. However, the trend toward improved EFS (HR 0.72) is encouraging and may become significant with longer follow-up and more data.\u003c\/p\u003e\n\n\u003cp\u003eFinally, the significantly higher rates of hematological toxicities—particularly anemia (15 times higher risk) and thrombocytopenia (8 times higher risk)—must be carefully considered. These side effects are manageable but may require additional treatments such as growth factors, blood transfusions, or dose reductions, and can significantly impact a patient's quality of life during treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eWhile this meta-analysis provides valuable evidence, it is important to understand its limitations. The researchers acknowledged several important constraints in their analysis.\u003c\/p\u003e\n\n\u003cp\u003eFirst, there was significant heterogeneity among the included trials. The I² statistic—which measures the degree of inconsistency in results across studies—was 56.3% for the overall pCR analysis, indicating moderate to substantial heterogeneity. This means the trials differed in ways beyond random chance, which could include differences in patient populations, chemotherapy regimens, and study designs.\u003c\/p\u003e\n\n\u003cp\u003eSecond, only two RCTs reported survival outcomes, limiting the statistical power to detect differences in EFS and OS. The confidence intervals for both survival endpoints were wide, meaning the true effects could be larger or smaller than observed.\u003c\/p\u003e\n\n\u003cp\u003eThird, the analysis of BRCA-mutated patients was based on only 96 patients from two trials, which limits the reliability of this subgroup analysis. The finding that BRCA-mutated patients did not benefit from platinum addition should be interpreted with caution.\u003c\/p\u003e\n\n\u003cp\u003eFourth, two RCTs did not report the specific rates of grade 3 and 4 adverse events in the two treatment arms, and two RCTs were published only in abstract form, which may limit the completeness of the safety data.\u003c\/p\u003e\n\n\u003cp\u003eFifth, the analysis of adverse events in two trials (GeparSixto GBG66 and UMIN000003355) included data from all patients in those trials, not just TNBC patients, under the assumption that the risk of adverse events would not be influenced by hormone receptor status. This could potentially introduce bias into the safety analysis.\u003c\/p\u003e\n\n\u003cp\u003eFinally, the median follow-up in the survival analyses was relatively short (39 and 47.3 months), and longer follow-up may reveal different survival outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on the findings of this meta-analysis, the researchers concluded that platinum-based neoadjuvant chemotherapy may be considered an option in TNBC patients. However, the decision to add a platinum agent should be made on an individual basis, taking into account the potential benefits and risks.\u003c\/p\u003e\n\n\u003cp\u003eIf you are a TNBC patient considering neoadjuvant chemotherapy, here are some key points to discuss with your oncology team:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about your pCR odds:\u003c\/strong\u003e The addition of platinum agents can increase your chance of achieving a pCR from approximately 37% to 52%. This means that for every 100 patients treated, about 15 additional patients would achieve a complete response with the addition of platinum.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss your BRCA status:\u003c\/strong\u003e If you have a BRCA gene mutation, the benefit of adding platinum is less clear based on current evidence. Your oncologist can help you understand whether platinum-based treatment is appropriate for your specific situation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand the side effect profile:\u003c\/strong\u003e Platinum-based chemotherapy significantly increases the risk of severe neutropenia (3 times higher), anemia (15 times higher), and thrombocytopenia (8 times higher). Ask your healthcare team how these side effects would be monitored and managed during your treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider the survival data:\u003c\/strong\u003e While pCR rates improved with platinum-based chemotherapy, the available data did not show a statistically significant improvement in event-free or overall survival. Ask your oncologist about the latest survival data and what it means for your prognosis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss your individual risk-benefit ratio:\u003c\/strong\u003e The decision to add platinum should consider your overall health, the stage and characteristics of your tumor, your tolerance for potential side effects, and your personal values and preferences.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials:\u003c\/strong\u003e If you are interested in platinum-based treatment, ask whether there are any ongoing clinical trials that might be appropriate for your situation. Clinical trials can provide access to emerging treatments and contribute to advancing knowledge in this area.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eRemember that every patient is unique, and treatment decisions should always be made in close consultation with your oncology team, who can provide personalized recommendations based on your specific circumstances.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is triple-negative breast cancer and why is it treated with chemotherapy before surgery?\u003c\/h3\u003e\n\u003cp\u003eTriple-negative breast cancer (TNBC) lacks receptors for estrogen, progesterone, and HER2, so hormone and HER2-targeted therapies are ineffective. Chemotherapy before surgery, called neoadjuvant chemotherapy, is preferred because TNBC is particularly sensitive to it, and achieving a pathological complete response (no tumor left) is strongly linked to better long-term outcomes.\u003c\/p\u003e\n\u003ch3\u003eDoes adding platinum chemotherapy improve survival for triple-negative breast cancer patients?\u003c\/h3\u003e\n\u003cp\u003eIn the two trials that reported survival, there was no statistically significant improvement in event-free survival or overall survival with platinum-based chemotherapy. The trend suggested a possible 28% reduction in events, but this was not conclusive. Longer follow-up and more trials are needed to determine if the improved complete response rates translate into better survival.\u003c\/p\u003e\n\u003ch3\u003eI have a BRCA gene mutation. Will platinum chemotherapy help me more?\u003c\/h3\u003e\n\u003cp\u003eSurprisingly, in this analysis of 96 BRCA-mutated patients, adding carboplatin did not significantly increase the complete response rate (58.0% vs 54.3%). However, the number of patients was small, so this finding is not definitive. Discuss your individual situation with your oncologist, as the decision to add platinum should be personalized.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main side effects of adding platinum chemotherapy?\u003c\/h3\u003e\n\u003cp\u003eAdding platinum significantly increases the risk of severe blood-related side effects: neutropenia (low white blood cells) is 3 times more likely, anemia (low red blood cells) is 15 times more likely, and thrombocytopenia (low platelets) is 8 times more likely. However, it does not increase the risk of severe neuropathy (nerve damage). These side effects are manageable but may require extra treatments.\u003c\/p\u003e\n\u003ch3\u003eIs the benefit of adding platinum the same for all chemotherapy backbones?\u003c\/h3\u003e\n\u003cp\u003eThe benefit was consistent across different chemotherapy backbones. In the three trials using the standard regimen of weekly paclitaxel followed by anthracycline plus cyclophosphamide, the complete response rate improved from 33.3% to 54.9% with the addition of carboplatin. This suggests the benefit is not limited to a specific combination.\u003c\/p\u003e\n\u003ch3\u003eShould I ask my oncologist about adding platinum to my neoadjuvant chemotherapy?\u003c\/h3\u003e\n\u003cp\u003eYes, discuss the potential benefits and risks. Adding platinum can increase your chance of a complete response from about 37% to 52%, but it also raises the risk of severe blood-related side effects. Your oncologist can help you weigh these factors based on your tumor characteristics, BRCA status, overall health, and personal preferences.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer- a systematic review and meta-analysis\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e \u003ca href=\"https:\/\/doi.org\/10.1093\/annonc\/mdy127\" target=\"_blank\" rel=\"noopener\"\u003e10.1093\/annonc\/mdy127\u003c\/a\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e F. Poggio, M. Bruzzone, M. Ceppi, N.F. Pondé, G. La Valle, L. Del Mastro, E. de Azambuja, and M. Lambertini\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Annals of Oncology, Volume 29, Issue 7, pages 1497–1508, 2018\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1093\/annonc\/mdy127\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublished:\u003c\/strong\u003e Online June 4, 2018\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePROSPERO Registration:\u003c\/strong\u003e CRD42018080042\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace professional medical advice. Always consult with your healthcare provider about treatment decisions.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47377200939164,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/platinum-based-chemotherapy-before-surgery-for-triple-negative-breast-cancer-what-patients-need-to-know","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}